Voyager Therapeutics (VYGR) Research & Development (2014 - 2026)

Voyager Therapeutics has disclosed Research & Development across 13 years of filings, most recently posting $22.0 million for Q2 2026.

• In Q2 2026, Research & Development fell 29.65% year-over-year to $22.0 million; the TTM figure through Jun 2026 stood at $118.5 million (down 7.94% YoY), while the FY2025 annual figure was $134.7 million, up 5.74% from the prior year.
• Research & Development came in at $22.0 million for Q2 2026 at Voyager Therapeutics, down from $24.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $36.0 million in Q4 2025 to a low of $12.5 million in Q2 2022.
• Average Research & Development over 5 years is $25.6 million, with a median of $25.8 million recorded in 2023.
• Year-over-year, Research & Development slumped 35.79% in 2022 and soared 77.01% in 2023.
• Over 5 years, Research & Development stood at $14.6 million in 2022, then soared by 77.01% to $25.8 million in 2023, then surged by 38.15% to $35.6 million in 2024, then rose by 1.04% to $36.0 million in 2025, then tumbled by 38.69% to $22.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $22.0 million in Q2 2026, $24.6 million in Q1 2026, and $36.0 million in Q4 2025.